Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Impact of SARS-CoV-2 vaccination and passive prophylaxis with tixagevimab/cilgavimab on CAR-T patients: a three-year regional experience from the Italian covid pandemic

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Heatmap of the prophylactic status of CAR-T patients according to the three enrollment ERAs.

Data availability

For data availability, please contact the corresponding author.


  1. Buske C, Dreyling M, Alvarez-Larrán A, Apperley J, Arcaini L, Besson C, et al. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus. ESMO Open. 2022;7:100403.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Pagano L, Salmanton-García J, Marchesi F, Blennow O, Gomes da Silva M, Glenthøj A, et al. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from EPICOVIDEHA survey. Blood. 2022;140:2773–87.

    Article  CAS  PubMed  Google Scholar 

  3. Spanjaart AM, Ljungman P, de La Camara R, Tridello G, Ortiz-Maldonado V, Urbano-Ispizua A, et al. Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group. Leukemia. 2021;35:3585–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Lemoine J, Bachy E, Cartron G, Beauvais D, Gastinne T, Rubio MT, et al. Causes and risk factors of early and late non-relapse mortality after CD19 CAR T-cell therapy for diffuse large B-cell lymphoma (DLBCL): a Lysa Study from the Descar-T Registry. Blood. 2022;140:1859–61.

    Article  Google Scholar 

  5. Agenzia Italiana del Farmaco Determina 15 febbraio 2022 Definizione delle modalita’ e delle condizioni di impiego dell’associazione di anticorpi monoclonali Evusheld (AZD7442; tixagevimab-cilgavimab) ai sensi del decreto 20 gennaio 2022. (Determina n. DG/87/2022) (22A01225). Accessed 25 Jan 2023.

  6. Infante MS, DeWolf S, Tamari R, Dahi PB, Lee YJ, Politikos I, et al. Outcomes and management of Sars-CoV2 Omicron variant in recipients of hematopoietic cell transplantation (HCT) and CAR-T therapy. Blood. 2022;140:4792–4.

    Article  Google Scholar 

  7. SARS-CoV-2 variants of concern as of 17 May 2023. Accessed 23 May 2023.

  8. Lin L, Liu Y, Tang X, He D. The disease severity and clinical outcomes of the SARS-CoV-2 variants of concern. Front Public Health. 2021;9:775224.

    Article  PubMed  PubMed Central  Google Scholar 

Download references


The authors acknowledge the support of “Centro di Ricerca sulle cellule staminali emopoietiche e le terapie cellulari “Università Cattolica del Sacro Cuore, Roma” research funding. The authors thank also John D. Marra, MD, for support in medical English.

Author information

Authors and Affiliations



EG, ADR, and FS designed the study and drafted the paper. SH, PC, SS, AC, API and MM supervised the study and critically revised the paper. NP and MB supervised the fluency of collection and management of cellular products. EG, ADR, MDP, IP, and FF collected data. EG performed statistical analysis. FF, EM and AC managed the infectious complications of patients. All authors have critically reviewed and approved the paper.

Corresponding author

Correspondence to Simona Sica.

Ethics declarations

Competing interests

EG received travel grants from Kite Gilead and honoraria for speakers bureau from Novartis and advisory board from Bristol Myers Squibb. SH received honoraria for participating to advisory boards from Novartis. PC received honoraria for participating to advisory boards from Bristol Myers Squibb and Novartis. All other authors declare no competing conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Galli, E., Di Rocco, A., Pansini, I. et al. Impact of SARS-CoV-2 vaccination and passive prophylaxis with tixagevimab/cilgavimab on CAR-T patients: a three-year regional experience from the Italian covid pandemic. Bone Marrow Transplant 58, 1394–1396 (2023).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


Quick links